Venture Fund Xlp Atlas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Venture fund xlp atlas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Venture Fund Xlp Atlas Today - Breaking & Trending Today

HC Wainwright Reaffirms "Buy" Rating for Kymera Therapeutics (NASDAQ:KYMR)

HC Wainwright reiterated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $46.00 target price on the stock. Several other analysts have also recently weighed in on KYMR. JPMorgan Chase & Co. raised their target price on shares […] ....

Stifel Nicolaus , Comerica Bank , Principal Financial Group Inc , Jpmorgan Chase Co , Venture Fund Xlp Atlas , Mirae Asset Global Investments Co , Kymera Therapeutics Company Profile , Wolfe Research , Congress Asset Management Co , Kymera Therapeutics Inc , Ameritas Investment Partners Inc , Kymera Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Bruce Booth , Venture Fund , Investment Partners , Asset Global Investments , Asset Management , Principal Financial Group , Financial Group , Kymera Therapeutics Daily ,

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $41.10

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among […] ....

United States , Brucen Jacobs , Stifel Nicolaus , Wolfe Research , Jpmorgan Chase Co , Raymond James Associates , Venture Fund Xlp Atlas , Kymera Therapeutics Inc , Barclays Plc , Td Asset Management Inc , Allspring Global Investments Holdings , Kymera Therapeutics Company Profile , Securities Exchange Commission , Kymera Therapeutics , Get Free Report , Marketbeat Ratings , Venture Fund , Exchange Commission , Management Inc , Global Investments Holdings , State Retirement System , Get Free , Kymera Therapeutics Daily ,

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 5.5%

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 5.5%
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United States , Brucen Jacobs , Stifel Nicolaus , Piper Sandler , Jpmorgan Chase Co , Wolfe Research , Venture Fund Xlp Atlas , Allspring Global Investments Holdings , Ameritas Investment Partners Inc , Securities Exchange Commission , China Universal Asset Management Co , Kymera Therapeutics Inc , Quest Partners , Kymera Therapeutics , Get Free Report , Therapeutics Stock Down , Venture Fund , Exchange Commission , Global Investments Holdings , State Retirement System , Universal Asset Management , Ameritas Investment Partners , Investment Partners , Kymera Therapeutics Daily ,

Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Stifel Nicolaus , Piper Sandler , Kymera Therapeutics Inc , Wolfe Research , Jpmorgan Chase Co , Venture Fund Xlp Atlas , Kymera Therapeutics , Get Free Report , Venture Fund , Director Bruce Booth , Kymera Therapeutics Daily ,

Kymera Therapeutics (NASDAQ:KYMR) Issues Earnings Results, Beats Expectations By $0.04 EPS

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return […] ....

Piper Sandler , Securities Exchange Commission , Wolfe Research , Kymera Therapeutics Company Profile , Venture Fund Xlp Atlas , Jpmorgan Chase Co , Kymera Therapeutics Inc , Kymera Therapeutics , Get Free Report , Director Bruce Booth , Exchange Commission , Venture Fund , Truist Financial , Kymera Therapeutics Daily , Nasdaq Kymr ,